1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY DIAGNOSTIC TECHNIQUES
5.1. Introduction
5.2. Imaging
5.2.1. Market Opportunities and Trends
5.2.2. Growth Prospects
5.2.3. Geographic Lucrativeness
5.3. Biopsy
5.3.1. Market Opportunities and Trends
5.3.2. Growth Prospects
5.3.3. Geographic Lucrativeness
5.4. Laboratory Tests
5.4.1. Market Opportunities and Trends
5.4.2. Growth Prospects
5.4.3. Geographic Lucrativeness
6. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY CANCER TYPE
6.1. Introduction
6.2. BRCA Breast Cancer
6.2.1. Market Opportunities and Trends
6.2.2. Growth Prospects
6.2.3. Geographic Lucrativeness
6.3. ER & PR Breast Cancer
6.3.1. Market Opportunities and Trends
6.3.2. Growth Prospects
6.3.3. Geographic Lucrativeness
6.4. HER 2 Breast Cancer
6.4.1. Market Opportunities and Trends
6.4.2. Growth Prospects
6.4.3. Geographic Lucrativeness
6.5. EGFR Mutation Test Breast Cancer
6.5.1. Market Opportunities and Trends
6.5.2. Growth Prospects
6.5.3. Geographic Lucrativeness
6.6. Others
6.6.1. Market Opportunities and Trends
6.6.2. Growth Prospects
6.6.3. Geographic Lucrativeness
7. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY END-USER
7.1. Introduction
7.2. Hospitals and Clinics
7.2.1. Market Opportunities and Trends
7.2.2. Growth Prospects
7.2.3. Geographic Lucrativeness
7.3. Cancer Research Centers
7.3.1. Market Opportunities and Trends
7.3.2. Growth Prospects
7.3.3. Geographic Lucrativeness
7.4. Diagnostic Laboratories
7.4.1. Market Opportunities and Trends
7.4.2. Growth Prospects
7.4.3. Geographic Lucrativeness
7.5. Others
7.5.1. Market Opportunities and Trends
7.5.2. Growth Prospects
7.5.3. Geographic Lucrativeness
8. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Diagnostic Techniques
8.2.2. By Cancer Type
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.1.1. Market Opportunities and Trends
8.2.4.1.2. Growth Prospects
8.2.4.2. Canada
8.2.4.2.1. Market Opportunities and Trends
8.2.4.2.2. Growth Prospects
8.2.4.3. Mexico
8.2.4.3.1. Market Opportunities and Trends
8.2.4.3.2. Growth Prospects
8.3. South America
8.3.1. By Diagnostic Techniques
8.3.2. By Cancer Type
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.1.1. Market Opportunities and Trends
8.3.4.1.2. Growth Prospects
8.3.4.2. Argentina
8.3.4.2.1. Market Opportunities and Trends
8.3.4.2.2. Growth Prospects
8.3.4.3. Others
8.3.4.3.1. Market Opportunities and Trends
8.3.4.3.2. Growth Prospects
8.4. Europe
8.4.1. By Diagnostic Techniques
8.4.2. By Cancer Type
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. Germany
8.4.4.1.1. Market Opportunities and Trends
8.4.4.1.2. Growth Prospects
8.4.4.2. France
8.4.4.2.1. Market Opportunities and Trends
8.4.4.2.2. Growth Prospects
8.4.4.3. UK
8.4.4.3.1. Market Opportunities and Trends
8.4.4.3.2. Growth Prospects
8.4.4.4. Italy
8.4.4.4.1. Market Opportunities and Trends
8.4.4.4.2. Growth Prospects
8.4.4.5. Belgium
8.4.4.5.1. Market Opportunities and Trends
8.4.4.5.2. Growth Prospects
8.4.4.6. Others
8.4.4.6.1. Market Opportunities and Trends
8.4.4.6.2. Growth Prospects
8.5. Middle East and Africa
8.5.1. By Diagnostic Techniques
8.5.2. By Cancer Type
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.1.1. Market Opportunities and Trends
8.5.4.1.2. Growth Prospects
8.5.4.2. UAE
8.5.4.2.1. Market Opportunities and Trends
8.5.4.2.2. Growth Prospects
8.5.4.3. Israel
8.5.4.3.1. Market Opportunities and Trends
8.5.4.3.2. Growth Prospects
8.5.4.4. Others
8.5.4.4.1. Market Opportunities and Trends
8.5.4.4.2. Growth Prospects
8.6. Asia Pacific
8.6.1. By Diagnostic Techniques
8.6.2. By Cancer Type
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.1.1. Market Opportunities and Trends
8.6.4.1.2. Growth Prospects
8.6.4.2. India
8.6.4.2.1. Market Opportunities and Trends
8.6.4.2.2. Growth Prospects
8.6.4.3. Japan
8.6.4.3.1. Market Opportunities and Trends
8.6.4.3.2. Growth Prospects
8.6.4.4. South Korea
8.6.4.4.1. Market Opportunities and Trends
8.6.4.4.2. Growth Prospects
8.6.4.5. Taiwan
8.6.4.5.1. Market Opportunities and Trends
8.6.4.5.2. Growth Prospects
8.6.4.6. Thailand
8.6.4.6.1. Market Opportunities and Trends
8.6.4.6.2. Growth Prospects
8.6.4.7. Indonesia
8.6.4.7.1. Market Opportunities and Trends
8.6.4.7.2. Growth Prospects
8.6.4.8. Australia
8.6.4.8.1. Market Opportunities and Trends
8.6.4.8.2. Growth Prospects
8.6.4.9. New Zealand
8.6.4.9.1. Market Opportunities and Trends
8.6.4.9.2. Growth Prospects
8.6.4.10. Others
8.6.4.10.1. Market Opportunities and Trends
8.6.4.10.2. Growth Prospects
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Abbott
10.2. Hologic Inc.
10.3. F. Hoffmann-La Roche Ltd
10.4. GE Healthcare
10.5. Thermo Fisher Scientific Inc.
10.6. Koninklijke Philips N.V.
10.7. Siemens AG
10.8. Fujifilm Holdings Corporation
10.9. Myriad Genetics
10.10. Carestream Health